Latest Japan Tobacco (JAPAF) Headlines Philip
Post# of 3
Posted On: 03/10/2014 8:03:37 AM
Latest Japan Tobacco (JAPAF) Headlines
Philip Morris International's European Problem Is Starting to Look Even Worse. Should You Be Concern
Ted Cooper, The Motley Fool - Motley Fool - Sat Mar 01, 7:15AM CST
Cigarette smoking is on the decline in Western nations, and there is nothing tobacco companies can do about it. Of particular concern to Philip Morris International is the sharp drop-off in cigarette volume in the European Union, where the company...
Tobacco Stemming and Redrying Industry in the U.S. and its International Trade [2014 Edition]: With Forecasts up to 2017
M2 - Thu Feb 27, 10:55AM CST
Research and Markets (http://www.researchandmarkets.com/research/6rlvmk/tobacco_stemming) has announced the addition of Supplier Relations US, LLC's new report "Tobacco Stemming and Redrying Industry in the U.S. and its International Trade [2014 Edition]" to their offering. The Tobacco Stemming and Redrying Industry report contains the most recent data and analysis on the industry's key financial data, cost and pricing, competitive landscape, industry structure. Also updated are the latest trade, shipment, and inventory data available through December 2013. This update provides the data necessary to make informed forecasts and business planning after the recent seasonal changes in output. This 158-page report includes the most recent information on the domestic market, global market and overseas growth opportunities. This report provides the most current data available, such as shipments, inventory and trade data available through December 2013, and sophisticated forecasts up to 2017 accounting for the affects of the recent economic recession. Industry analysts consider this report the most comprehensive and consistently updated guide to the industry. Revenue, Profitability & Foreign Trade Preview The industry's revenue for the year 2012 was reported at $1.5 billion USD, with an estimated gross profit of 33.99%. The industry used a projected 64 percent of its full production capacity in 2012. The industry could have increased its total shipment value to $2.3 billion USD under full production capacity. This industry did not have direct foreign trade statistics. The report nevertheless depicted relevant foreign trade data from a higher level NAICS industry or industry group. Companies Mentioned - Imperial Tobacco Group plc - Japan Tobacco Inc. - Philip Morris USA Inc. - Reynolds American Inc. - Star Scientific Inc. - Universal Corporation For more information visit http://www.researchandmarkets.com/research/6r...o_stemming Source: Supplier Relations US, LLC About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Global HIV Drug Forecast and Market Analysis to 2022
M2 - Thu Feb 27, 4:13AM CST
Research and Markets (http://www.researchandmarkets.com/research/vwjjw9/pharmapoint_hiv) has announced the addition of the "Global HIV Drug Forecast and Market Analysis to 2022" report to their offering. China's HIV Drug Market Revenue to Plummet 65% by 2020 A growing generics sector, combined with the introduction of compulsory licensing, will lead to a dramatic revenue drop in China's HIV therapeutics market in the near future, predicts research and consulting firm The authors. HIV drug sales in China to fall from a 2012 valuation of US$374m to US$129m in 2020 at a negative Compound Annual Growth Rate (CAGR) of 12.5%. The primary factor in this expected revenue depreciation is the increased dominance of generic drug use amongst Chinese physicians. Before the end of the decade, patents for key HIV drugs including AbbVie's Norvir, Janssen's Prezista and Merck's Crixivan are due to expire, leaving the market open to the entrance of much cheaper generic variants. A generic version of ViiV's Epzicom will enter the Chinese market in 2016, followed by Gilead's Truvada and Atripla drugs in 2018. However, China's recently amended intellectual property laws could mean these treatments - if declared to be of public interest - face compulsory licensing before their respective patent expiration dates. Compulsory licensing will make HIV drugs available to a much larger segment of the HIV positive population. China is adopting aggressive healthcare policies to identify newly infected people and connect them with the appropriate level of treatment to limit viral transmission. Use of branded drugs would result in an increased financial burden for the Chinese government, but compulsory licensing can potentially make treatment for all infected people a reality. However, while the adoption of compulsory licensing potentially increases the size of the treated population, it limits the attractiveness of the market for pharmaceutical companies. The authors new report forecasts the global HIV therapeutics market to decrease in value from US$11.4 billion in 2012 to US$10.8 billion in 2022, representing a negative CAGR of 1% over the 10 year period. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview 4 Epidemiology 5 Disease Management 6 Competitive Assessment 7 Opportunity and Unmet Need 8 Pipeline Assessment 9 Current and Future Players 10 Market Outlook 11 Appendix Companies Mentioned - Gilead - ViiV Healthcare - AbbVie (Abbott) - Merck - Janssen (a Subsidiary of J&J) - Bristol-Myers Squibb - Japan Tobacco - Avexa - TaiMed Biologics - Tobira Therapeutics For more information visit http://www.researchandmarkets.com/research/vw...apoint_hiv
Cigarettes in Mexico
M2 - Mon Feb 10, 4:05AM CST
In 2012, Japan Tobacco International Mexico S de RL de CV started to distribute one of its brands, Winston, independently. Winston's portfolio includes Winston Classic (tar level 10mg) and Winston Blue (tar level 8mg), which are available in 14s and 20s. Winston's launch in Mexico was supported by the creation of a Facebook page and free sampling during the LMFAO (an American electronic dance music duo) tour.
Japanese Firm Invests K12 Million in Tobacco Farming
by Kennedy Mupseni - All Africa Global Media - Fri Jan 31, 6:54AM CST
JAPAN Tobacco International (JTI) Leaf Zambia has invested K12 million on inputs and out-grower schemes for tobacco production in this year's farming season.
2013 Report on the Japanese HIV Drug Market - Forecasts to 2022
M2 - Mon Jan 20, 4:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/l4jfdl/pharmapoint_hiv) has announced the addition of the "2013 Report on the Japanese HIV Drug Market - Forecasts to 2022" report to their offering. The treatment algorithm in HIV has characteristically involved multiple drug regimens designed to tackle the virus on different levels. In the recent past, simplified dosing regimens through the emergence of single tablet regimens (STRs) or fixed dose combination (FDC) therapies have become increasingly popular amongst physicians and patients alike by increasing clinical efficacy thresholds and enabling patient compliance. This can be explained by the low prevalence and incidence rates of HIV in Japan. Human Immunodeficiency Virus (HIV), the causative agent of AIDS, has claimed millions of lives since its emergence. However, the advent of antiretroviral therapy (ART) has transformed the face of HIV/AIDS from a deadly disease to a manageable chronic condition for most infected individuals. Antiretroviral treatment not only reduces the viral load and reconstitutes immune function, but also decreases infection incidence rates by limiting viral transmission The Japanese market is different from the other major markets in that STR use has not yet been introduced. For example, Atripla, which is the market leader in the US and Europe, is not currently licensed in Japan. However, the first integrase-based STR, Gilead's Stribild, which was approved by the FDA in August 2012, might be launched in Japan by the end of 2013 or at the beginning of 2014. Japan Tobacco, through its research alliance with Gilead, filed for market approval of elvitegravir in December 2012 with the Japanese Ministry of Health, Labour and Welfare. It is forecasted that ViiV will adopt a similar approach to launch the novel INI-based inhibitor dolutegravir and 572-Trii into the Japanese market. Key Topics Covered: 1 List of Tables and Figures 2 Introduction 3 Disease Overview 4 Disease Management 5 Competitive Assessment 6 Opportunity and Unmet Need 7 Pipeline Assessment 8 Market Outlook 9 Appendix For more information visit http://www.researchandmarkets.com/research/l4...apoint_hiv
Don't Give up on Philip Morris, the Company Still Has Plenty of Room for Growth
Rupert Hargreaves, The Motley Fool - Motley Fool - Fri Jan 10, 7:00AM CST
At the end of last year, Philip Morris International's management team revealed that the company's growth was going to be below its long-term target of 10% per annum during 2014. Specifically, management stated that 2014 was going to be a year of...
2013 Report on Cigarette Manufacturing Industry Features Players such as Loews Corporation and Star Scientific Inc.
M2 - Tue Jan 07, 10:06AM CST
Research and Markets (http://www.researchandmarkets.com/research/chrtq5/cigarette) has announced the addition of Supplier Relations US, LLC's new report "Cigarette Manufacturing Industry in the U.S. and its International Trade [2013 Q4 Edition]" to their offering. This 2013 year-end publication of Cigarette Manufacturing Industry report is the comprehensive market research guide for the industry. It contains the latest information on the industry's key financial data, competitive landscape, cost and pricing, and trends during the current environment, including the output and shipment changes over the past months. The industry's revenue for the year 2012 was reported at $31.9 billion USD, with an estimated gross profit of 86.47%. Import was valued at $140.3 million USD from 20 countries. The industry also exported $360.9 million USD worth of merchandise to 67 countries. Adding import value to and subtracting export value from the industry's shipment value, the total domestic demand for the industry in 2012 was $31.7 billion USD. This industry report contains 154 pages of in-depth market research with over 150 charts and tables. Presented are current and forecasted U.S. industry sales and shipment data, and its global trade statistics. For financial analysis, the report presents industry level income statements, balance sheets, and capital expenditure figures. In the cost analysis section, 40 upstream industries are analyzed to offer insight into the supply chain cost structure. For the channel and pricing structure, 3 downstream industries are analyzed. The competitive landscape section provides the number of companies and their respective revenue share, the market concentration, and a list of major players. Furthermore, products within the industry are listed with their respective market sizes and import and export data. The appendices contain relevant resources to additional trade statistics, U.S. State statistics, and industry trade associations. Companies Mentioned: - Altria Group, Inc. - British American Tobacco Company - Imperial Tobacco Group plc - Japan Tobacco Inc. - Loews Corporation - Philip Morris USA Inc. - R.J. Reynolds Tobacco Co. - Reynolds American Inc. - Star Scientific Inc. - Vector Group Ltd. For more information visit http://www.researchandmarkets.com/research/chrtq5/cigarette Source: Supplier Relations US, LLC About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Turnitin Webcasts to Address Plagiarism Prevention and Improving Critical Thinking Skills
PR Newswire - Tue Jan 07, 10:00AM CST
Turnitin, the leader in originality checking and online grading, today announced its Winter 2014 schedule of free 30-minute webcasts with a focus on using technology to provide impactful feedback to students and reduce incidents of plagiarism. The popular weekly series had nearly 25,000 registrants for the live 30-minute sessions in 2013. Another 18,000 educators viewed the recorded sessions last year.
UK Cigarettes & Tobacco Market Report 2013
M2 - Tue Dec 10, 9:51AM CST
Research and Markets (http://www.researchandmarkets.com/research/vpt9l7/cigarettes_and) has announced the addition of the "Cigarettes & Tobacco Market Report 2013" report to their offering. This Market Report analyses the cigarettes and tobacco market in the UK. It covers various types of smoking tobacco products, with the analysis focused on items that are sold in the retail sector. The total value for retail sales of cigarettes and tobacco products grew by 6.4% and 2.4%, respectively, in 2011 and 2012. The increase in market value was driven primarily by price increases and government tax hikes on these products. Official statistics show that the proportion of smokers in Great Britain has been falling steadily since 1974, due to increased awareness of the health risks involved in smoking, and legislative restrictions implemented by the Government, such as the smoking ban in public places and the ban on cigarette vending machines. The economic downturn in 2008 also contributed to the downwards trend as some consumers decided to quit smoking due to financial problems. In 2011, 20% of the total adult population in Great Britain smoked, down from 27% in 2000 and 45% in 1974. Traditional manufactured cigarettes continued to account for the largest sector of the market over the review period, with the sector growing year-on-year between 2010 and 2012. Prior to that, the traditional cigarette market contracted by 0.6% in 2009, affected by the economic downturn. Sales of hand-rolling tobacco (HRT) grew throughout the review period, with the sector rising by an estimated 31.1% between 2008 and 2012. Growth in HRT has been driven by the increasing number of smokers switching from cigarettes to HRT to save money. The UK cigar and pipe tobacco sectors were in long-term decline well before the recent economic downturn and continue to fall in value. In 2012, sales of cigar and pipe tobacco products fell by 7.3% and 36.7%, respectively. The market is dominated by a handful of tobacco companies, including Philip Morris International (PMI); British American Tobacco (BAT); Imperial Tobacco; and Japan Tobacco International (JTI). These companies operate on a global scale and have a combined share of nearly half the global market. In order to remain competitive, large tobacco companies are beginning to adopt alternatives to traditional cigarettes, such as electric cigarettes (e-cigarettes). The authors forecast that the UK market for cigarettes and tobacco will continue to grow in value terms over the next 5 years, driven mainly by greater tax hikes and price increases. Companies Mentioned - British American Tobacco PLC - Hunters and Frankau Ltd - Imperial Tobacco Group PLC - Japan Tobacco International - Philip Morris International - Republic Technologies (UK) Ltd - Ronson International Ltd For more information visit http://www.researchandmarkets.com/research/vp...rettes_and
Philip Morris Buying 20% Stake in Russian Distributor Megapolis
Patrick Morris, The Motley Fool - Motley Fool - Wed Dec 04, 12:25PM CST
Today, Philip Morris International announced it would be acquiring a 20% stake in Megapolis Distribution BV , for $750 million. Megapolis is Philip Morris International's distributor in Russia, which is the second-largest cigarette market in...
2 Factors that Philip Morris Needs to Be Worried About
Rupert Hargreaves, The Motley Fool - Motley Fool - Thu Nov 07, 8:00AM CST
Philip Morris' recent fiscal third quarter earnings report revealed that the company was struggling on many fronts. The most important factor was the company's sliding number of cigarettes sold in comparison to its peers. In particular, Philip...
Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2013 Financial Results
GlobeNewswire - Mon Nov 04, 3:30PM CST
Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of renal disease (the "Company"), today announced its results for the third quarter ended September 30, 2013.
Tobacco Stemming and Redrying Industry's Revenue for 2012 was Reported at $1.5 Billion USD, With an Estimated Gross Profit of 27.57% says 2013 Report
M2 - Fri Oct 18, 8:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bltthx/tobacco_stemming) has announced the addition of Supplier Relations US, LLC's Updated report "Tobacco Stemming and Redrying Industry in the U.S. and its International Trade [2013 Q3 Edition]" to their offering. The industry used a projected 64 percent of its full production capacity in 2012. The industry could have increased its total shipment value to $2.3 billion USD under full production capacity. This industry did not have direct foreign trade statistics. The report nevertheless depicted relevant foreign trade data from a higher level NAICS industry or industry group. Report Summary This 158-page report contains unparalleled industry market research in breadth and depth, providing a comprehensive view of the industry within the context of the overall manufacturing economy. The report's supply and demand data covers U.S. shipments and international trade while also considering the industry's capacity utilization. The industry level income statements, balance sheets, and capital expenditure analysis contain all the necessary data for financial benchmarking. In the cost analysis section, 40 upstream industries are analyzed to offer insight into the supply chain cost structure. For the channel and pricing structure, 3 downstream industries are analyzed. The competitive landscape section reports on the number of firms and their industry revenue share, market concentration, and a list of major players. Related trade associations, industry standards, and trade publications are also listed. Companies Mentioned: - Imperial Tobacco Group plc - Japan Tobacco Inc. - Philip Morris USA Inc. - Reynolds American Inc. - Star Scientific Inc. - Universal Corporation For more information visit http://www.researchandmarkets.com/research/bl...o_stemming Source: Supplier Relations US, LLC About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Cigarettes - 2013 Global Strategic Business Report Featuring British American Tobacco, China National Tobacco, Imperial Tobacco, Japan Tobacco, and Philip Morris
GlobeNewswire - Mon Oct 07, 10:06AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wllhjd/cigarettes) has announced the addition of the "Cigarettes - Global Strategic Business Report" report to their offering.
Allergies - Pipeline Review, H2 2013 Reviews Key Players Involved In the Therapeutic Development for Allergies
M2 - Mon Sep 02, 12:23PM CDT
Research and Markets (http://www.researchandmarkets.com/research/2kfdwp/allergies) has announced the addition of the "Allergies - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Allergies - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Allergies, complete with latest updates, and special features on late-stage and discontinued projects. Allergies - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Allergies. - A review of the Allergies products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Allergies pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - ALK-Abello A/S - ANERGIS SA - Actelion Ltd - ActogeniX NV - Antigen Express, Inc. - AstraZeneca PLC - BioLineRx, Ltd. - Biomay AG - Biotec Pharmacon ASA - Clarassance, Inc. - Cytos Biotechnology AG - Dainippon Sumitomo Pharma Co., Ltd. - EpiVax, Inc. - GlaxoSmithKline plc - Idera Pharmaceuticals, Inc. - Immune Design Inc. - ImmunoFrontier, Inc. - Immupharma Plc - Indus Biotech Private Limited - IntelGenx Technologies Corp. - Interprotein Corporation - Japan Tobacco Inc. - Monosol Rx, LLC - NAL Pharmaceuticals Ltd. - Novartis AG - Proteo, Inc. - RaQualia Pharma Inc. - SIFI S.p.A - Shionogi & Co., Ltd. - SuppreMol GmbH - ToleroTech Inc. - United Biomedical, Inc. - Vaxine Pty Ltd - Viromed Co., Ltd. - Xencor, Inc. For more information visit http://www.researchandmarkets.com/research/2kfdwp/allergies About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Analyzing the Global Tobacco Industry 2013
M2 - Fri Aug 30, 9:07AM CDT
Research and Markets (http://www.researchandmarkets.com/research/nmm4qr/analyzing_the) has announced the addition of the "Analyzing the Global Tobacco Industry 2013" report to their offering. There is no denying the fact that in spite of a global economic downturn, lawsuits, health problems, and rising prices of cigarettes, the global tobacco industry has continued to generate strong growth as well as profits. Many legal problems continue to plague the global tobacco industry as governments around the world continue to put in place strict regulations to curb the use of tobacco. The health impact of tobacco are many and many smokers are suffering from cancer or other side effects of tobacco consumption. While tobacco majors continue to initiate campaigns to stop children from consuming tobacco, they are also pursuing research and development efforts to develop cigarettes that reduce the health risks related with smoking. One of the major challenge facing the tobacco industry is the growth of discount cigarette manufacturers who are not involved in the settlement with US state governments, and are gaining market share rapidly. The report is an in-depth profile of the tobacco industry in many countries, along with a complete analysis of the major players in the industry. For the global tobacco industry we analyze the industry through an industry definition, industry overview wherein we look at the market statistics, an industry value analysis, industry segmentation, regional share of the industry, industry distribution, along with an analysis of the competition in the industry and company market share. Future of the global tobacco industry is also analyzed. For each of the country profiles, we analyze the tobacco market through an industry overview, industry value analysis, industry segmentation, regional share analysis, industry distribution, market competition, major players in the market and their market share, as well as an analysis of the future of the tobacco market in the country. Key Topics Covered: A. Executive Summary B. Global Tobacco Industry C. Tobacco Industry in Australia D. Tobacco Industry in Belgium E. Tobacco Industry in Brazil F. Tobacco Industry in Canada G. Tobacco Industry in China H. Tobacco Industry in Czech Republic I. Tobacco Industry in Denmark J. Tobacco Industry in France K. Tobacco Industry in Germany L. Tobacco Industry in Hungary M. Tobacco Industry in Italy N. Tobacco Industry in India O. Tobacco Industry in Japan P. Tobacco Industry in Mexico Q. Tobacco Industry in Netherlands R. Tobacco Industry in Norway S. Tobacco Industry in Poland T. Tobacco Industry in Russia U. Tobacco Industry in Singapore V. Tobacco Industry in South Africa W. Tobacco Industry in South Korea X. Tobacco Industry in Spain Y. Tobacco Industry in Sweden Z. Tobacco Industry in Taiwan AA. Tobacco Industry in United Kingdom BB. Tobacco Industry in United States CC. Analysis of Major Industry Players - Altria Group, Inc - Amergon Corporation - British American Tobacco Plc - China National Tobacco Corporation - Cojimar Cigar Co. - Godfrey Phillips India Ltd. - Golden Tobacco Limited - Imperial Tobacco Group PLC - ITC Limited - Japan Tobacco Inc. - Korea Tobacco & Ginseng Corporation - Langaard - Lorillard - Philip Morris International Inc. - Reynolds American, Inc. - Scandinavian Tobacco Group - Souza Cruz SA - Swedish Match AB - Taiwan Tobacco and Liquor For more information visit http://www.researchandmarkets.com/research/nm...lyzing_the
Cigarette Manufacturing Industry in the U.S. and its International Trade - 2013 Report on the $31.9 Billion Market
M2 - Thu Aug 29, 10:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/s6mt95/cigarette) has announced the addition of Supplier Relations US, LLC's new report "Cigarette Manufacturing Industry in the U.S. and its International Trade [2013 Q3 Edition]" to their offering. The industry's revenue for the year 2012 was reported at $31.9 billion USD, with an estimated gross profit of 86.47%. Import was valued at $140.3 million USD from 20 countries. The industry also exported $360.9 million USD worth of merchandise to 67 countries. Adding import value to and subtracting export value from the industry's shipment value, the total domestic demand for the industry in 2012 was $31.7 billion USD. This 2013 report's 155 pages and over 150 charts and tables cover the domestic market, global market and overseas growth opportunities. Find the latest data on shipments, inventory, international trade, and essential industry price indices available through June 2013. Relying on over a decade of historic data and sophisticated forecasting, the report projects industry trends through 2017. The report's broad scope includes topics from foreign trade to industry structure, while also diving into the details such as market sizes of products and players. Industry experts consistently subscribe to this quarterly-updated market research report. In this report, you will find industry data on the following major categories: - Executive Summary - Industry Income Statement - Industry Balance Sheet - Capital Expenditure - Industry Cost Analysis - Industry Pricing Analysis - Industry Foreign Trade - Industry Structure - Competitive Landscape Companies Mentioned - Altria Group, Inc. - British American Tobacco Company - Imperial Tobacco Group plc - Japan Tobacco Inc. - Loews Corporation - Philip Morris USA Inc. - R.J. Reynolds Tobacco Co. - Reynolds American Inc. - Star Scientific Inc. - Vector Group Ltd. For more information visit http://www.researchandmarkets.com/research/s6mt95/cigarette Source: Supplier Relations US, LLC
Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2013 Financial Results
GlobeNewswire - Wed Jul 31, 3:30PM CDT
Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of renal disease (the "Company"), today announced its results for the second quarter ended June 30, 2013.
Anemia - Pipeline Review, H2 2012
M2 - Fri Jul 26, 3:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hnwr7f/anemia_pipeline) has announced the addition of the "Anemia - Pipeline Review, H2 2012" report to their offering. This research provides an overview of the Anemia therapeutic pipeline. This report provides information on the therapeutic development for Anemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Anemia. The data is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Scope - A snapshot of the global therapeutic scenario for Anemia. - A review of the Anemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Anemia pipeline on the basis of route of administration and molecule type. - Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress. - Key discontinued pipeline projects. Key Topics Covered: List of Tables List of Figures Introduction REPORT COVERAGE Anemia Overview Therapeutics Development An Overview of Pipeline Products for Anemia Anemia Therapeutics under Development by Companies Anemia Therapeutics under Investigation by Universities/Institutes Late Stage Products Comparative Analysis Mid Clinical Stage Products Comparative Analysis Early Clinical Stage Products Comparative Analysis Discovery and Pre-Clinical Stage Products Comparative Analysis Companies Involved in Anemia Therapeutics Development Drug Profiles Anemia Therapeutics - Drug Profile Updates Anemia Therapeutics - Discontinued Products Anemia Therapeutics - Dormant Products Anemia - Product Development Milestones Featured News & Press Releases Appendix Companies Mentioned: - 3SBio - AMAG Pharmaceuticals - Amgen - Aspen Pharmacare Holdings - Bayer AG - Chong Kun Dang Pharmaceutical - Daiichi Sankyo Company - Dong-A Pharmaceutical Co - Eli Lilly and Company - Evotec Aktiengesellschaft - FibroGen. - Galenica - Gamida Cell - GlaxoSmithKline - Hospira - Inovio Biomedical Corporation - Insmed Incorporated - Japan Tobacco - Johnson & Johnson - Kyowa Hakko Kirin Co - Lentigen Corporation - Medgenics - Medinox - Novartis AG - Pfizer - Reliance Life Sciences Pvt - Rockwell Medical Technologies - Sangamo BioSciences - Sangart. - Zosano Pharma - Zydus Cadila Healthcare Limited For more information visit http://www.researchandmarkets.com/research/hn...a_pipeline
Philip Morris International's European Problem Is Starting to Look Even Worse. Should You Be Concern
Ted Cooper, The Motley Fool - Motley Fool - Sat Mar 01, 7:15AM CST
Cigarette smoking is on the decline in Western nations, and there is nothing tobacco companies can do about it. Of particular concern to Philip Morris International is the sharp drop-off in cigarette volume in the European Union, where the company...
Tobacco Stemming and Redrying Industry in the U.S. and its International Trade [2014 Edition]: With Forecasts up to 2017
M2 - Thu Feb 27, 10:55AM CST
Research and Markets (http://www.researchandmarkets.com/research/6rlvmk/tobacco_stemming) has announced the addition of Supplier Relations US, LLC's new report "Tobacco Stemming and Redrying Industry in the U.S. and its International Trade [2014 Edition]" to their offering. The Tobacco Stemming and Redrying Industry report contains the most recent data and analysis on the industry's key financial data, cost and pricing, competitive landscape, industry structure. Also updated are the latest trade, shipment, and inventory data available through December 2013. This update provides the data necessary to make informed forecasts and business planning after the recent seasonal changes in output. This 158-page report includes the most recent information on the domestic market, global market and overseas growth opportunities. This report provides the most current data available, such as shipments, inventory and trade data available through December 2013, and sophisticated forecasts up to 2017 accounting for the affects of the recent economic recession. Industry analysts consider this report the most comprehensive and consistently updated guide to the industry. Revenue, Profitability & Foreign Trade Preview The industry's revenue for the year 2012 was reported at $1.5 billion USD, with an estimated gross profit of 33.99%. The industry used a projected 64 percent of its full production capacity in 2012. The industry could have increased its total shipment value to $2.3 billion USD under full production capacity. This industry did not have direct foreign trade statistics. The report nevertheless depicted relevant foreign trade data from a higher level NAICS industry or industry group. Companies Mentioned - Imperial Tobacco Group plc - Japan Tobacco Inc. - Philip Morris USA Inc. - Reynolds American Inc. - Star Scientific Inc. - Universal Corporation For more information visit http://www.researchandmarkets.com/research/6r...o_stemming Source: Supplier Relations US, LLC About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Global HIV Drug Forecast and Market Analysis to 2022
M2 - Thu Feb 27, 4:13AM CST
Research and Markets (http://www.researchandmarkets.com/research/vwjjw9/pharmapoint_hiv) has announced the addition of the "Global HIV Drug Forecast and Market Analysis to 2022" report to their offering. China's HIV Drug Market Revenue to Plummet 65% by 2020 A growing generics sector, combined with the introduction of compulsory licensing, will lead to a dramatic revenue drop in China's HIV therapeutics market in the near future, predicts research and consulting firm The authors. HIV drug sales in China to fall from a 2012 valuation of US$374m to US$129m in 2020 at a negative Compound Annual Growth Rate (CAGR) of 12.5%. The primary factor in this expected revenue depreciation is the increased dominance of generic drug use amongst Chinese physicians. Before the end of the decade, patents for key HIV drugs including AbbVie's Norvir, Janssen's Prezista and Merck's Crixivan are due to expire, leaving the market open to the entrance of much cheaper generic variants. A generic version of ViiV's Epzicom will enter the Chinese market in 2016, followed by Gilead's Truvada and Atripla drugs in 2018. However, China's recently amended intellectual property laws could mean these treatments - if declared to be of public interest - face compulsory licensing before their respective patent expiration dates. Compulsory licensing will make HIV drugs available to a much larger segment of the HIV positive population. China is adopting aggressive healthcare policies to identify newly infected people and connect them with the appropriate level of treatment to limit viral transmission. Use of branded drugs would result in an increased financial burden for the Chinese government, but compulsory licensing can potentially make treatment for all infected people a reality. However, while the adoption of compulsory licensing potentially increases the size of the treated population, it limits the attractiveness of the market for pharmaceutical companies. The authors new report forecasts the global HIV therapeutics market to decrease in value from US$11.4 billion in 2012 to US$10.8 billion in 2022, representing a negative CAGR of 1% over the 10 year period. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview 4 Epidemiology 5 Disease Management 6 Competitive Assessment 7 Opportunity and Unmet Need 8 Pipeline Assessment 9 Current and Future Players 10 Market Outlook 11 Appendix Companies Mentioned - Gilead - ViiV Healthcare - AbbVie (Abbott) - Merck - Janssen (a Subsidiary of J&J) - Bristol-Myers Squibb - Japan Tobacco - Avexa - TaiMed Biologics - Tobira Therapeutics For more information visit http://www.researchandmarkets.com/research/vw...apoint_hiv
Cigarettes in Mexico
M2 - Mon Feb 10, 4:05AM CST
In 2012, Japan Tobacco International Mexico S de RL de CV started to distribute one of its brands, Winston, independently. Winston's portfolio includes Winston Classic (tar level 10mg) and Winston Blue (tar level 8mg), which are available in 14s and 20s. Winston's launch in Mexico was supported by the creation of a Facebook page and free sampling during the LMFAO (an American electronic dance music duo) tour.
Japanese Firm Invests K12 Million in Tobacco Farming
by Kennedy Mupseni - All Africa Global Media - Fri Jan 31, 6:54AM CST
JAPAN Tobacco International (JTI) Leaf Zambia has invested K12 million on inputs and out-grower schemes for tobacco production in this year's farming season.
2013 Report on the Japanese HIV Drug Market - Forecasts to 2022
M2 - Mon Jan 20, 4:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/l4jfdl/pharmapoint_hiv) has announced the addition of the "2013 Report on the Japanese HIV Drug Market - Forecasts to 2022" report to their offering. The treatment algorithm in HIV has characteristically involved multiple drug regimens designed to tackle the virus on different levels. In the recent past, simplified dosing regimens through the emergence of single tablet regimens (STRs) or fixed dose combination (FDC) therapies have become increasingly popular amongst physicians and patients alike by increasing clinical efficacy thresholds and enabling patient compliance. This can be explained by the low prevalence and incidence rates of HIV in Japan. Human Immunodeficiency Virus (HIV), the causative agent of AIDS, has claimed millions of lives since its emergence. However, the advent of antiretroviral therapy (ART) has transformed the face of HIV/AIDS from a deadly disease to a manageable chronic condition for most infected individuals. Antiretroviral treatment not only reduces the viral load and reconstitutes immune function, but also decreases infection incidence rates by limiting viral transmission The Japanese market is different from the other major markets in that STR use has not yet been introduced. For example, Atripla, which is the market leader in the US and Europe, is not currently licensed in Japan. However, the first integrase-based STR, Gilead's Stribild, which was approved by the FDA in August 2012, might be launched in Japan by the end of 2013 or at the beginning of 2014. Japan Tobacco, through its research alliance with Gilead, filed for market approval of elvitegravir in December 2012 with the Japanese Ministry of Health, Labour and Welfare. It is forecasted that ViiV will adopt a similar approach to launch the novel INI-based inhibitor dolutegravir and 572-Trii into the Japanese market. Key Topics Covered: 1 List of Tables and Figures 2 Introduction 3 Disease Overview 4 Disease Management 5 Competitive Assessment 6 Opportunity and Unmet Need 7 Pipeline Assessment 8 Market Outlook 9 Appendix For more information visit http://www.researchandmarkets.com/research/l4...apoint_hiv
Don't Give up on Philip Morris, the Company Still Has Plenty of Room for Growth
Rupert Hargreaves, The Motley Fool - Motley Fool - Fri Jan 10, 7:00AM CST
At the end of last year, Philip Morris International's management team revealed that the company's growth was going to be below its long-term target of 10% per annum during 2014. Specifically, management stated that 2014 was going to be a year of...
2013 Report on Cigarette Manufacturing Industry Features Players such as Loews Corporation and Star Scientific Inc.
M2 - Tue Jan 07, 10:06AM CST
Research and Markets (http://www.researchandmarkets.com/research/chrtq5/cigarette) has announced the addition of Supplier Relations US, LLC's new report "Cigarette Manufacturing Industry in the U.S. and its International Trade [2013 Q4 Edition]" to their offering. This 2013 year-end publication of Cigarette Manufacturing Industry report is the comprehensive market research guide for the industry. It contains the latest information on the industry's key financial data, competitive landscape, cost and pricing, and trends during the current environment, including the output and shipment changes over the past months. The industry's revenue for the year 2012 was reported at $31.9 billion USD, with an estimated gross profit of 86.47%. Import was valued at $140.3 million USD from 20 countries. The industry also exported $360.9 million USD worth of merchandise to 67 countries. Adding import value to and subtracting export value from the industry's shipment value, the total domestic demand for the industry in 2012 was $31.7 billion USD. This industry report contains 154 pages of in-depth market research with over 150 charts and tables. Presented are current and forecasted U.S. industry sales and shipment data, and its global trade statistics. For financial analysis, the report presents industry level income statements, balance sheets, and capital expenditure figures. In the cost analysis section, 40 upstream industries are analyzed to offer insight into the supply chain cost structure. For the channel and pricing structure, 3 downstream industries are analyzed. The competitive landscape section provides the number of companies and their respective revenue share, the market concentration, and a list of major players. Furthermore, products within the industry are listed with their respective market sizes and import and export data. The appendices contain relevant resources to additional trade statistics, U.S. State statistics, and industry trade associations. Companies Mentioned: - Altria Group, Inc. - British American Tobacco Company - Imperial Tobacco Group plc - Japan Tobacco Inc. - Loews Corporation - Philip Morris USA Inc. - R.J. Reynolds Tobacco Co. - Reynolds American Inc. - Star Scientific Inc. - Vector Group Ltd. For more information visit http://www.researchandmarkets.com/research/chrtq5/cigarette Source: Supplier Relations US, LLC About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Turnitin Webcasts to Address Plagiarism Prevention and Improving Critical Thinking Skills
PR Newswire - Tue Jan 07, 10:00AM CST
Turnitin, the leader in originality checking and online grading, today announced its Winter 2014 schedule of free 30-minute webcasts with a focus on using technology to provide impactful feedback to students and reduce incidents of plagiarism. The popular weekly series had nearly 25,000 registrants for the live 30-minute sessions in 2013. Another 18,000 educators viewed the recorded sessions last year.
UK Cigarettes & Tobacco Market Report 2013
M2 - Tue Dec 10, 9:51AM CST
Research and Markets (http://www.researchandmarkets.com/research/vpt9l7/cigarettes_and) has announced the addition of the "Cigarettes & Tobacco Market Report 2013" report to their offering. This Market Report analyses the cigarettes and tobacco market in the UK. It covers various types of smoking tobacco products, with the analysis focused on items that are sold in the retail sector. The total value for retail sales of cigarettes and tobacco products grew by 6.4% and 2.4%, respectively, in 2011 and 2012. The increase in market value was driven primarily by price increases and government tax hikes on these products. Official statistics show that the proportion of smokers in Great Britain has been falling steadily since 1974, due to increased awareness of the health risks involved in smoking, and legislative restrictions implemented by the Government, such as the smoking ban in public places and the ban on cigarette vending machines. The economic downturn in 2008 also contributed to the downwards trend as some consumers decided to quit smoking due to financial problems. In 2011, 20% of the total adult population in Great Britain smoked, down from 27% in 2000 and 45% in 1974. Traditional manufactured cigarettes continued to account for the largest sector of the market over the review period, with the sector growing year-on-year between 2010 and 2012. Prior to that, the traditional cigarette market contracted by 0.6% in 2009, affected by the economic downturn. Sales of hand-rolling tobacco (HRT) grew throughout the review period, with the sector rising by an estimated 31.1% between 2008 and 2012. Growth in HRT has been driven by the increasing number of smokers switching from cigarettes to HRT to save money. The UK cigar and pipe tobacco sectors were in long-term decline well before the recent economic downturn and continue to fall in value. In 2012, sales of cigar and pipe tobacco products fell by 7.3% and 36.7%, respectively. The market is dominated by a handful of tobacco companies, including Philip Morris International (PMI); British American Tobacco (BAT); Imperial Tobacco; and Japan Tobacco International (JTI). These companies operate on a global scale and have a combined share of nearly half the global market. In order to remain competitive, large tobacco companies are beginning to adopt alternatives to traditional cigarettes, such as electric cigarettes (e-cigarettes). The authors forecast that the UK market for cigarettes and tobacco will continue to grow in value terms over the next 5 years, driven mainly by greater tax hikes and price increases. Companies Mentioned - British American Tobacco PLC - Hunters and Frankau Ltd - Imperial Tobacco Group PLC - Japan Tobacco International - Philip Morris International - Republic Technologies (UK) Ltd - Ronson International Ltd For more information visit http://www.researchandmarkets.com/research/vp...rettes_and
Philip Morris Buying 20% Stake in Russian Distributor Megapolis
Patrick Morris, The Motley Fool - Motley Fool - Wed Dec 04, 12:25PM CST
Today, Philip Morris International announced it would be acquiring a 20% stake in Megapolis Distribution BV , for $750 million. Megapolis is Philip Morris International's distributor in Russia, which is the second-largest cigarette market in...
2 Factors that Philip Morris Needs to Be Worried About
Rupert Hargreaves, The Motley Fool - Motley Fool - Thu Nov 07, 8:00AM CST
Philip Morris' recent fiscal third quarter earnings report revealed that the company was struggling on many fronts. The most important factor was the company's sliding number of cigarettes sold in comparison to its peers. In particular, Philip...
Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2013 Financial Results
GlobeNewswire - Mon Nov 04, 3:30PM CST
Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of renal disease (the "Company"), today announced its results for the third quarter ended September 30, 2013.
Tobacco Stemming and Redrying Industry's Revenue for 2012 was Reported at $1.5 Billion USD, With an Estimated Gross Profit of 27.57% says 2013 Report
M2 - Fri Oct 18, 8:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bltthx/tobacco_stemming) has announced the addition of Supplier Relations US, LLC's Updated report "Tobacco Stemming and Redrying Industry in the U.S. and its International Trade [2013 Q3 Edition]" to their offering. The industry used a projected 64 percent of its full production capacity in 2012. The industry could have increased its total shipment value to $2.3 billion USD under full production capacity. This industry did not have direct foreign trade statistics. The report nevertheless depicted relevant foreign trade data from a higher level NAICS industry or industry group. Report Summary This 158-page report contains unparalleled industry market research in breadth and depth, providing a comprehensive view of the industry within the context of the overall manufacturing economy. The report's supply and demand data covers U.S. shipments and international trade while also considering the industry's capacity utilization. The industry level income statements, balance sheets, and capital expenditure analysis contain all the necessary data for financial benchmarking. In the cost analysis section, 40 upstream industries are analyzed to offer insight into the supply chain cost structure. For the channel and pricing structure, 3 downstream industries are analyzed. The competitive landscape section reports on the number of firms and their industry revenue share, market concentration, and a list of major players. Related trade associations, industry standards, and trade publications are also listed. Companies Mentioned: - Imperial Tobacco Group plc - Japan Tobacco Inc. - Philip Morris USA Inc. - Reynolds American Inc. - Star Scientific Inc. - Universal Corporation For more information visit http://www.researchandmarkets.com/research/bl...o_stemming Source: Supplier Relations US, LLC About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Cigarettes - 2013 Global Strategic Business Report Featuring British American Tobacco, China National Tobacco, Imperial Tobacco, Japan Tobacco, and Philip Morris
GlobeNewswire - Mon Oct 07, 10:06AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wllhjd/cigarettes) has announced the addition of the "Cigarettes - Global Strategic Business Report" report to their offering.
Allergies - Pipeline Review, H2 2013 Reviews Key Players Involved In the Therapeutic Development for Allergies
M2 - Mon Sep 02, 12:23PM CDT
Research and Markets (http://www.researchandmarkets.com/research/2kfdwp/allergies) has announced the addition of the "Allergies - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Allergies - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Allergies, complete with latest updates, and special features on late-stage and discontinued projects. Allergies - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Allergies. - A review of the Allergies products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Allergies pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - ALK-Abello A/S - ANERGIS SA - Actelion Ltd - ActogeniX NV - Antigen Express, Inc. - AstraZeneca PLC - BioLineRx, Ltd. - Biomay AG - Biotec Pharmacon ASA - Clarassance, Inc. - Cytos Biotechnology AG - Dainippon Sumitomo Pharma Co., Ltd. - EpiVax, Inc. - GlaxoSmithKline plc - Idera Pharmaceuticals, Inc. - Immune Design Inc. - ImmunoFrontier, Inc. - Immupharma Plc - Indus Biotech Private Limited - IntelGenx Technologies Corp. - Interprotein Corporation - Japan Tobacco Inc. - Monosol Rx, LLC - NAL Pharmaceuticals Ltd. - Novartis AG - Proteo, Inc. - RaQualia Pharma Inc. - SIFI S.p.A - Shionogi & Co., Ltd. - SuppreMol GmbH - ToleroTech Inc. - United Biomedical, Inc. - Vaxine Pty Ltd - Viromed Co., Ltd. - Xencor, Inc. For more information visit http://www.researchandmarkets.com/research/2kfdwp/allergies About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Analyzing the Global Tobacco Industry 2013
M2 - Fri Aug 30, 9:07AM CDT
Research and Markets (http://www.researchandmarkets.com/research/nmm4qr/analyzing_the) has announced the addition of the "Analyzing the Global Tobacco Industry 2013" report to their offering. There is no denying the fact that in spite of a global economic downturn, lawsuits, health problems, and rising prices of cigarettes, the global tobacco industry has continued to generate strong growth as well as profits. Many legal problems continue to plague the global tobacco industry as governments around the world continue to put in place strict regulations to curb the use of tobacco. The health impact of tobacco are many and many smokers are suffering from cancer or other side effects of tobacco consumption. While tobacco majors continue to initiate campaigns to stop children from consuming tobacco, they are also pursuing research and development efforts to develop cigarettes that reduce the health risks related with smoking. One of the major challenge facing the tobacco industry is the growth of discount cigarette manufacturers who are not involved in the settlement with US state governments, and are gaining market share rapidly. The report is an in-depth profile of the tobacco industry in many countries, along with a complete analysis of the major players in the industry. For the global tobacco industry we analyze the industry through an industry definition, industry overview wherein we look at the market statistics, an industry value analysis, industry segmentation, regional share of the industry, industry distribution, along with an analysis of the competition in the industry and company market share. Future of the global tobacco industry is also analyzed. For each of the country profiles, we analyze the tobacco market through an industry overview, industry value analysis, industry segmentation, regional share analysis, industry distribution, market competition, major players in the market and their market share, as well as an analysis of the future of the tobacco market in the country. Key Topics Covered: A. Executive Summary B. Global Tobacco Industry C. Tobacco Industry in Australia D. Tobacco Industry in Belgium E. Tobacco Industry in Brazil F. Tobacco Industry in Canada G. Tobacco Industry in China H. Tobacco Industry in Czech Republic I. Tobacco Industry in Denmark J. Tobacco Industry in France K. Tobacco Industry in Germany L. Tobacco Industry in Hungary M. Tobacco Industry in Italy N. Tobacco Industry in India O. Tobacco Industry in Japan P. Tobacco Industry in Mexico Q. Tobacco Industry in Netherlands R. Tobacco Industry in Norway S. Tobacco Industry in Poland T. Tobacco Industry in Russia U. Tobacco Industry in Singapore V. Tobacco Industry in South Africa W. Tobacco Industry in South Korea X. Tobacco Industry in Spain Y. Tobacco Industry in Sweden Z. Tobacco Industry in Taiwan AA. Tobacco Industry in United Kingdom BB. Tobacco Industry in United States CC. Analysis of Major Industry Players - Altria Group, Inc - Amergon Corporation - British American Tobacco Plc - China National Tobacco Corporation - Cojimar Cigar Co. - Godfrey Phillips India Ltd. - Golden Tobacco Limited - Imperial Tobacco Group PLC - ITC Limited - Japan Tobacco Inc. - Korea Tobacco & Ginseng Corporation - Langaard - Lorillard - Philip Morris International Inc. - Reynolds American, Inc. - Scandinavian Tobacco Group - Souza Cruz SA - Swedish Match AB - Taiwan Tobacco and Liquor For more information visit http://www.researchandmarkets.com/research/nm...lyzing_the
Cigarette Manufacturing Industry in the U.S. and its International Trade - 2013 Report on the $31.9 Billion Market
M2 - Thu Aug 29, 10:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/s6mt95/cigarette) has announced the addition of Supplier Relations US, LLC's new report "Cigarette Manufacturing Industry in the U.S. and its International Trade [2013 Q3 Edition]" to their offering. The industry's revenue for the year 2012 was reported at $31.9 billion USD, with an estimated gross profit of 86.47%. Import was valued at $140.3 million USD from 20 countries. The industry also exported $360.9 million USD worth of merchandise to 67 countries. Adding import value to and subtracting export value from the industry's shipment value, the total domestic demand for the industry in 2012 was $31.7 billion USD. This 2013 report's 155 pages and over 150 charts and tables cover the domestic market, global market and overseas growth opportunities. Find the latest data on shipments, inventory, international trade, and essential industry price indices available through June 2013. Relying on over a decade of historic data and sophisticated forecasting, the report projects industry trends through 2017. The report's broad scope includes topics from foreign trade to industry structure, while also diving into the details such as market sizes of products and players. Industry experts consistently subscribe to this quarterly-updated market research report. In this report, you will find industry data on the following major categories: - Executive Summary - Industry Income Statement - Industry Balance Sheet - Capital Expenditure - Industry Cost Analysis - Industry Pricing Analysis - Industry Foreign Trade - Industry Structure - Competitive Landscape Companies Mentioned - Altria Group, Inc. - British American Tobacco Company - Imperial Tobacco Group plc - Japan Tobacco Inc. - Loews Corporation - Philip Morris USA Inc. - R.J. Reynolds Tobacco Co. - Reynolds American Inc. - Star Scientific Inc. - Vector Group Ltd. For more information visit http://www.researchandmarkets.com/research/s6mt95/cigarette Source: Supplier Relations US, LLC
Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2013 Financial Results
GlobeNewswire - Wed Jul 31, 3:30PM CDT
Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of renal disease (the "Company"), today announced its results for the second quarter ended June 30, 2013.
Anemia - Pipeline Review, H2 2012
M2 - Fri Jul 26, 3:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hnwr7f/anemia_pipeline) has announced the addition of the "Anemia - Pipeline Review, H2 2012" report to their offering. This research provides an overview of the Anemia therapeutic pipeline. This report provides information on the therapeutic development for Anemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Anemia. The data is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Scope - A snapshot of the global therapeutic scenario for Anemia. - A review of the Anemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Anemia pipeline on the basis of route of administration and molecule type. - Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress. - Key discontinued pipeline projects. Key Topics Covered: List of Tables List of Figures Introduction REPORT COVERAGE Anemia Overview Therapeutics Development An Overview of Pipeline Products for Anemia Anemia Therapeutics under Development by Companies Anemia Therapeutics under Investigation by Universities/Institutes Late Stage Products Comparative Analysis Mid Clinical Stage Products Comparative Analysis Early Clinical Stage Products Comparative Analysis Discovery and Pre-Clinical Stage Products Comparative Analysis Companies Involved in Anemia Therapeutics Development Drug Profiles Anemia Therapeutics - Drug Profile Updates Anemia Therapeutics - Discontinued Products Anemia Therapeutics - Dormant Products Anemia - Product Development Milestones Featured News & Press Releases Appendix Companies Mentioned: - 3SBio - AMAG Pharmaceuticals - Amgen - Aspen Pharmacare Holdings - Bayer AG - Chong Kun Dang Pharmaceutical - Daiichi Sankyo Company - Dong-A Pharmaceutical Co - Eli Lilly and Company - Evotec Aktiengesellschaft - FibroGen. - Galenica - Gamida Cell - GlaxoSmithKline - Hospira - Inovio Biomedical Corporation - Insmed Incorporated - Japan Tobacco - Johnson & Johnson - Kyowa Hakko Kirin Co - Lentigen Corporation - Medgenics - Medinox - Novartis AG - Pfizer - Reliance Life Sciences Pvt - Rockwell Medical Technologies - Sangamo BioSciences - Sangart. - Zosano Pharma - Zydus Cadila Healthcare Limited For more information visit http://www.researchandmarkets.com/research/hn...a_pipeline
(0)
(0)Japan Tobacco (JAPAF) Stock Research Links
Scroll down for more posts ▼